Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

The B.C. government is restricting the sales of two more diabetes drugs to people outside Canada amid rising demand for the ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Many US employers plan to pare health benefits as weight-loss spending soars - Nation and World News | Hawaii Tribune-Herald ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...